Preprint Short Note Version 1 Preserved in Portico This version is not peer-reviewed

Mass Intake of Hydroxychloroquine or Chloroquine in the Present Context of the COVID-19 Outbreak: Possible Consequences in Endemic Malaria Settings

Version 1 : Received: 12 April 2020 / Approved: 13 April 2020 / Online: 13 April 2020 (07:47:36 CEST)

A peer-reviewed article of this Preprint also exists.


World is currently experiencing a new pandemic for which no curative treatment is available. At this time, coronavirus disease 2019 (Covid-19) has reached 183 countries and has caused several deaths. Many reports presented chloroquine (CQ) and hydrochloroquine (HCQ), former drugs used against malaria, as the best current choice to fight this terrible disease. As these molecules had been withdrawn in malaria treatment policy due to chemoresistance, their reintroduction could have some consequences. Though local malaria prevalence could decrease for a while, molecular changes are likely to happen on some plasmodium falciparum genes involved in conferring drug resistance. This could threaten efforts in malaria control, if these molecules are widely administered.


malaria; COVID-19; SARS-COV-2; chloroquine; hydroxychloroquine


Medicine and Pharmacology, Pharmacology and Toxicology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.